Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1

Johnson & Johnson's SGLT2 inhibitor Invokana (canagliflozin)--among a handful of drugs in the new category of DPP-4 drugs for diabetes--not only took a big jump in sales for the first quarter but also made some significant market-share gains.

Janssen looks to Ichor's electroporation delivery system for hep B jab

San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.

IBM partners with Medtronic, J&J, Apple to use Big Data to optimize healthcare coaching and diabetes care

IBM increased its presence in the device world in a major way, announcing a collaboration around famous supercomputer Watson with Medtronic, Johnson & Johnson and Apple.

Devices continue to disappoint at J&J, but orthopedics, electrophysiology lead the way

Johnson & Johnson's device strategy of divesting its worst performing businesses--while pushing forward with the rollout of innovative products--has yet to pay off. But the company is hopeful that it can return the business to sales growth over the next year.

J&J to use drug delivery device for HBV vaccine thanks to $85M partnership

J&J's Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B.

Currency hurts, Olysio plummets, but J&J pharma growth carries on

Johnson & Johnson revealed that its hepatitis C drug Olysio succumbed to U.S. competition. With Gilead Sciences' two-in-one pill Harvoni and AbbVie's Viekira Pak now on the scene, the J&J drug saw sales drop by two-thirds--and it was one of J&J's biggest pharma-growth drivers last year.

J&J partners with startup for DNA vaccine, hand-held device to treat HBV in $85M+ deal

Janssen Pharmaceuticals has paired up with Ichor Medical Systems to develop and market DNA-based vaccine products to treat chronic hepatitis B. The partners will use the startup's TriGrid electroporation technology for clinical administration of a DNA vaccine.

Big Pharma-backed Dutch immuno-oncology player eyes €100M Nasdaq IPO

A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.

J&J's Ethicon gets FDA clearance to use Evarrest patch for liver surgery

Johnson & Johnson's Ethicon division received clearance from the FDA for an expanded indication of its Evarrest patch, which can now be used to help control bleeding during adult liver surgery.

Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.